Clinical Trials on Tumor Scanning with ¹⁰³Ru

Abstract

Ruthenium-103 was used in scintigraphy of 37 patients with various types of malignant tumors. Malignant tumors were delineated as strongly positive in 54% of cases and slightly positive in 27% of cases. Head and neck tumors were identified as strongyl positive in 10 out of 13 cases (77%) and as slightly positive in 3 out of 13 cases (23%) . Primary lung cancer was strongly positive in 6 out of 8 cases (75%) . Two cases of hepatoma were not identified by ruthenium nuclides or by ⁶⁷Ga-citrate. Two case with inflammatory lesions showed a positive scan by ruthenium nuclides. The ruthenium radionuclides are, therefore, probably not suitable for differentiating carcinoma from inflammatory states. In four lung cancer patients, the uptake ratio of the tumor activety-to-normal symmetrical area activity was between 1.35-2.45 and did not undergo changes at 22 to 27 days after administration of ¹⁰³Ru.